<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088959</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00886</org_study_id>
    <secondary_id>4939-04-6R2</secondary_id>
    <secondary_id>DUMC-4939-03-6R0</secondary_id>
    <secondary_id>VAMC-DURHAM-00813</secondary_id>
    <secondary_id>DUMC-GCRC-911</secondary_id>
    <secondary_id>CDR0000377689</secondary_id>
    <secondary_id>DUMC-4939-04-6R2</secondary_id>
    <secondary_id>U01CA096123</secondary_id>
    <nct_id>NCT00088959</nct_id>
  </id_info>
  <brief_title>Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I Study of Erlotinib and Celecoxib in Former Smokers With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of celecoxib when given&#xD;
      together with erlotinib in treating former smokers with stage IIIB, stage IV, recurrent, or&#xD;
      progressive non-small cell lung cancer. Celecoxib and erlotinib may stop the growth of tumor&#xD;
      cells by blocking the enzymes necessary for their growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate the clinical toxicity and tolerability of erlotinib combined with celecoxib in&#xD;
      patients with advanced non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the tumor response rate of erlotinib combined with celecoxib in patients with&#xD;
      advanced NSCLC.&#xD;
&#xD;
      II. To estimate the dose of celecoxib that results in maximal induction of apoptosis, maximal&#xD;
      inhibition of prostaglandin E2 (PGE2) in bronchoalveolar (BAL) fluid, and maximal inhibition&#xD;
      of bronchial cell proliferation when combined with erlotinib.&#xD;
&#xD;
      III. To estimate the effect of erlotinib and the combination of erlotinib and celecoxib on&#xD;
      bronchial expression of COX-2.&#xD;
&#xD;
      IV. To estimate the effect of erlotinib and the combination of erlotinib (and celecoxib on&#xD;
      autophosphorylation of epidermal growth factor receptor (EGFR) in skin and endobronchial&#xD;
      biopsies.&#xD;
&#xD;
      V. To estimate the degree of correlation of autophosphorylation of EGFR in skin and&#xD;
      endobronchial samples.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the effect of the combination of erlotinib and COX-2 inhibitor (celecoxib) on&#xD;
      the frequency of fractional allelic loss (FAL) in endobronchial biopsies, metaplasia and&#xD;
      dysplasia in endobronchial biopsies, and endobronchial proliferation.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of celecoxib.&#xD;
&#xD;
      Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily.&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of celecoxib until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity. Once the MTD is determined, up to 6 additional patients&#xD;
      are treated at the MTD.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical tolerable dose of celecoxib as measured by NCI CTCAE v3.0</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride, celecoxib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (erlotinib hydrochloride, celecoxib)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (erlotinib hydrochloride, celecoxib)</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>SC-58635</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride, celecoxib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) meeting 1&#xD;
             of the following stage criteria: Stage IIIB with pleural effusion; Stage IV disease;&#xD;
             recurrent or progressive disease after prior surgery, radiotherapy, and/or&#xD;
             chemotherapy&#xD;
&#xD;
          -  If the sole prior treatment was in the adjuvant or neoadjuvant setting, tumor&#xD;
             progression or recurrence must have occurred within 6 months after completion of prior&#xD;
             treatment&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 10 g/dL&#xD;
&#xD;
          -  Hemostasis normal&#xD;
&#xD;
          -  Creatinine =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
          -  No uncontrolled dysrhythmia&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  FEV1 &gt;= 1.0 liter OR 40% of predicted within the past 3 months&#xD;
&#xD;
          -  Oxygen saturation &gt;= 90% on room air&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             treatment&#xD;
&#xD;
          -  Willing to undergo bronchoscopy&#xD;
&#xD;
          -  No allergy to sulfonamides or hypersensitivity reaction to celecoxib&#xD;
&#xD;
          -  No other medical or psychological condition (e.g., acute psychosis) that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin)&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  Prior complete resection allowed provided there is histologic and cytologic&#xD;
             documentation of disease recurrence&#xD;
&#xD;
          -  More than 3 months since prior chemopreventative agents (e.g., oltipraz, retinoids, or&#xD;
             N-acetylcysteine [NAC])&#xD;
&#xD;
          -  No prior erlotinib hydrochloride&#xD;
&#xD;
          -  No other prior EGFR antagonists&#xD;
&#xD;
          -  No concurrent medication known to interact with erlotinib hydrochloride or celecoxib,&#xD;
             including the following: Fluconazole, Lithium, Furosemide, Angiotensin-converting&#xD;
             enzyme inhibitors, Phenytoin, Carbamazepine, Rifampin, Barbiturates, Hypericum&#xD;
             perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Concurrent aspirin of up to an average dose of 325 mg/day allowed&#xD;
&#xD;
          -  No aspirin treatment for 7 days prior to any bronchoscopic or skin biopsy&#xD;
&#xD;
          -  No other concurrent EGFR inhibitors or cyclo-oxygenase-2 (COX-2) inhibitors&#xD;
&#xD;
          -  Meets 1 of the following criteria: 1) Advanced NSCLC with at least stable disease&#xD;
             after &gt;= 4 courses of platinum-containing chemotherapy 2) Relapsed or refractory&#xD;
             disease after treatment with &gt;= 1 prior platinum-containing chemotherapy program,&#xD;
             including adjuvant or neoadjuvant therapy for NSCLC&#xD;
&#xD;
          -  No untreated brain metastases&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Former smoker, as indicated by the following: 1) At least a 30 pack-year smoking&#xD;
             history 2) Smoking duration at least 10 years 3) At least 12 months of self-reported&#xD;
             smoking cessation 4) Negative urine cotinine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kelley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

